Терапевтический потенциал мелатонина при болезни Паркинсона: от нормализации циркадианных ритмов к нейропротекции

1. Литвиненко И.В., Красаков И.В., Тихомирова О.В. Нарушения сна у больных с деменцией при болезни Паркинсона. Журн. неврол. и психиат. 2011; 111 (9):37–42.
2. Литвиненко И.В. Эффективность и безопасность применения галантамина (реминила) в случаях деменции при болезни Паркинсона. Журн. неврол. и психиат. 2010; 107 (12): 21–9.
3. Adi N. Melatonin MT1 and MT2 receptor expression in Parkinson’s disease. Med SciMonit 2010; 16: BR61-BR67.
4. Anderson KN, Shneerson JM. Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. J Clin Sleep Med 2009; 5: 235–9.
5. Anderson KN. REM sleep behavior disorder treated with melatonin in a patient with Alzheimer’s disease. Clin Neurol Neurosurg 2008; 110: 492–5.
6. Acuña-Castroviejo D. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 1997; 60 (2): PL23–9.
7. Acuña-Antolín I. Protective effect of melatonin in a chronic experimental model of Parkinson's disease. Brain Res 2002; 943 (2): 163–73.
8. Boeve BF, Silber M, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 2003; 4: 281–4.
9. Cai Y. Expression of clock genes Per1 and Bmal1 in total leukocytes in health and Parkinson’s disease.J Neurol 2010 17: 550–4.
10. Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol 72: 517–49.
11. Fukuya H. Circadian expression of clock genes in human peripheral leukocytes. Biochem Biophys Res Commun 2007; 354: 924–8.
12. Grace JB, Walker MP, McKeith I. A comparison of sleep profiles in patients with dementia with Lewy bodies and Alzheimer’s disease. Int J Geriatr Psychiatry 2000; 15: 1028–33.
13. Hauser RA. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord 2009; 24 (7): 979–83.
14. Kondratov RV. Early aging and age-related pathologies in mice deficient in BMAL1, the core component of the circadian clock. Genes Dev 2006; 20: 1868–73.
15. Kunz D, Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov Disord 1999; 14: 507–11.
16. Lapierre O, Montplaisir J. Polysomnographic features of REM sleep behavior disorder: Development of a scoring method. Neurology 1992; 42: 1371–4.
17. LeWitt PA. Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment. J Neural Transm Suppl. 1994; 43: 171–81.
18. Maclean LE, Collins CC, Byrne EJ. Dementia with Lewy bodies treated with rivastigmine: Effects on cognition, neuropsychiatric symptoms, and sleep. Int Psychogeriatr 2001; 13: 277–88.
19. Massironi G, Galluzzi S, Frisoni GB. Drug treatment of REM sleep behavior disorders in dementia with Lewy bodies. Int Psychogeriatr 2003; 15: 377–83.
20. Niederhofer H. Donepezil in the treatment of narcolepsy. J Clin Sleep Med 2006; 2 (1): 71–2.
21. Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000; 123: 331–9.
22. Ono K. Effect of melatonin on a-synuclein self-assembly and cytotoxicity. Neurobiol Aging 2011 available online Nov 23.
23. Rye DB. Contributions of the pedunculopontine region to normal and altered REM sleep. Sleep 1997; 20: 757–88.
24. Schenck CH, Mahowald MW. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am J Med 1996; 100: 333–7.
25. Schuld A. Obstructive sleep apnea syndrome induced by clonazepam in a narcoleptic patient with REM-sleep-behavior disorder. J Sleep Res 1999; 8 (4): 321–2.
26. Schenck CH, Mahowald MW. A polysomnographic, neurologic, psychiatric, and clinical outcome report on 70 consecutive cases with REM sleep behavior disorder (RBD): sustained clonazepam efficacy in 89.5% of 57 treated patients. Clev Clin J Med 1990; 57(Suppl.): S9–S23.
27. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 2004; 291 (3): 358–64.
28. Shults CW. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002; 59 (10): 1541–50.
29. Saravanan KS, Sindhu KM, Mohanakumar KP. Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model. J Pineal Res 2007; 42 (3): 247–53.
30. Singhal NK. Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation? Mol Neurobiol 2012; 45 (1): 186–99.
31. Takeuchi N. Melatonin therapy for REM sleep behavior disorder. Psychiatr Clin Neurosci 2001; 55: 267–9.
32. Terzioglu M, Galter D. Parkinson's disease: genetic versus toxin-induced rodent models. FEBS J 2008; 275 (7): 1384–91.
33. Thomas B, Mohanakumar K. Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. J Pineal Res 2004; 36 (1): 25–32.
34. Wing YK. REM sleep behaviour disorder in Hong Kong Chinese: clinical outcome and gender comparison. J Neurol Neurosurg Psychiatry 2008; 79 (12): 1415–6.
35. Ward CD. Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 1994; 57 (2): 217–20.
36. Zeevalk G. Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethylester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp Neurol 2007; 203 (2): 512–20.

И.В.Литвиненко, И.В.Красаков 

Кафедра нервных болезней ВМА им. С.М.Кирова, Санкт-Петербург